PC712
Anti-p53 Binding Protein 1 (Ab-1) Rabbit pAb
liquid, Calbiochem®
别名:
Anti-53BP1
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.43
UNSPSC Code:
12352203
Clone:
polyclonal
Species reactivity:
mouse, human
Application:
—
Citations:
16
biological source
rabbit
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
form
liquid
does not contain
preservative
species reactivity
mouse, human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
dilution
(Immunoblotting (1:3000-1:5000)
Immunofluorescence (1:300-1:500, indirect)
Immunoprecipitation (1:300-1:500))
isotype
IgG
shipped in
wet ice
storage temp.
−70°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... TP53(7157)
General description
Purified rabbit polyclonal antibody. Recognizes the ~230 kDa 53BP1 protein.
Recognizes the ~230 kDa 53BP1 protein in HeLa cell nuclear extract (Cat. No. WB64).
This Anti-p53 Binding Protein 1 (Ab-1) Rabbit pAb is validated for use in Immunoblotting, Immunofluorescence, Immunoprecipitation for the detection of p53 Binding Protein 1 (Ab-1).
Immunogen
Human
a recombinant protein consisting of human 53BP1 fused to a His•Tag sequence
Application
Immunoblotting (1:3000-1:5000)
Immunofluorescence (1:300-1:500, indirect)
Immunoprecipitation (1:300-1:500)
Immunofluorescence (1:300-1:500, indirect)
Immunoprecipitation (1:300-1:500)
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 100 mM NaCl, 50 mM Tris-HCl, 20% glycerol, pH 7.6.
Preparation Note
Following initial thaw, aliquot and freeze (-70°C).
Analysis Note
Positive Control
HeLa Cell Nuclear Extract (Cat. No. WB64)
HeLa Cell Nuclear Extract (Cat. No. WB64)
Other Notes
Antibody should be titrated for optimal results in individual systems.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Mafuka Suzuki et al.
PloS one, 18(1), e0281168-e0281168 (2023-01-28)
Malignancy is often associated with therapeutic resistance and metastasis, usually arising after therapeutic treatment. These include radio- and chemo-therapies, which cause cancer cell death by inducing DNA double strand breaks (DSBs). However, it is still unclear how resistance to these
Mariana Acevedo et al.
Cancer research, 76(11), 3252-3264 (2016-05-22)
Promyelocytic leukemia (PML) plays a tumor suppressive role by inducing cellular senescence in response to oncogenic stress. However, tumor cell lines fail to engage in complete senescence upon PML activation. In this study, we investigated the mechanisms underlying resistance to
Hiroshi Ikeuchi et al.
Oncogene (2024-08-03)
Identifying the mechanisms of action of anticancer drugs is an important step in the development of new drugs. In this study, we established a comprehensive screening platform consisting of 68 oncogenes (MANO panel), encompassing 243 genetic variants, to identify predictive
Salma Akter et al.
Genes to cells : devoted to molecular & cellular mechanisms, 28(1), 53-67 (2022-11-24)
Steroid hormones induce the transcription of target genes by activating nuclear receptors. Early transcriptional response to various stimuli, including hormones, involves the active catalysis of topoisomerase II (TOP2) at transcription regulatory sequences. TOP2 untangles DNAs by transiently generating double-strand breaks
Haruka Fujimori et al.
Heliyon, 5(12), e03057-e03057 (2020-02-23)
Most cancers develop with one of two types of genomic instability, namely, chromosomal instability (CIN) or microsatellite instability (MSI). Both are induced by replication stress-associated DNA double-strand breaks (DSBs). The type of genomic instability that arises is dependent on the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持